Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Berberine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.87 |
| ▸ | ACHE | P22303 | 9/20 | 0.87 |
| ▸ | EP300 | Q09472 | 5/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
| ▸ | MAPT | P10636 | 2/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.87 |
| ▸ | DRD2 | P14416 | 2/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.87 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.87 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.87 |
| ▸ | RXRA | P19793 | 2/20 | 0.87 |
| ▸ | DRD1 | P21728 | 2/20 | 0.87 |
| ▸ | HTR2B | P41595 | 2/20 | 0.87 |
| ▸ | HTT | P42858 | 2/20 | 0.87 |
| ▸ | RAD52 | P43351 | 2/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Berberine SCHEMBL29570291 | 1.00 | BCHE (0.87) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL15672948 | 0.99 | BCHE (0.85) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL16781367 | 0.96 | ACHE (0.90) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL94112 | 0.96 | ACHE (0.90) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL15669190 | 0.93 | ACHE (1.00) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL29354144 | 0.93 | ACHE (1.00) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL30153843 | 0.93 | ACHE (1.00) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL25632 | 0.93 | ACHE (1.00) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL3686872 | 0.92 | BCHE (0.90) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL21462194 | 0.92 | ACHE (0.98) | BCHEACHEEP300ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1002 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120130513-A | Sterilization composition for preventing and treating cowpea root rot | 广西壮族自治区农业科学院 | 2025-06-13 | — | — | CN | claimed |
| CN-115192550-B | Chitosan/pullulan microfiber carrier, preparation method thereof, slow-release drug, preparation method thereof and pharmaceutical composition | 苏州大学 | 2025-05-13 | — | — | CN | claimed |
| CN-119423097-A | Multiple-effect plant growth regulator | 湖南省禾源生态农业发展有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119421708-A | Eriodictyol compositions and methods | CAS资产有限责任公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119391404-A | Aggregation-induced emission glycyrrhizic acid nanoparticle and preparation method and application thereof | 华南理工大学 | 2025-02-07 | — | — | CN | claimed |
| US-20250032455-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2025-01-30 | — | — | US | claimed |
| EP-4486449-A2 | ERIODICTYOL COMPOSITIONS AND METHODS | CAS Properties, LLC (US) | 2025-01-08 | — | — | EP | claimed |
| US-12171748-B2 | Nitroimidazole formulations | IRP Health Pty Ltd (AU) | 2024-12-24 | — | — | US | claimed |
| CN-119033675-A | All-natural aggregation-induced luminescent glycyrrhizic acid active hydrogel and preparation method and application thereof | 华南理工大学 | 2024-11-29 | — | — | CN | claimed |
| US-20240306670-A1 | BERBERINE ALKALOIDS IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL DISEASE | IRP Health Pty Ltd (AU) | 2024-09-19 | — | — | US | claimed |
| WO-2004093876-A2 | COMPOSITION CONTAINING BERBERINE OR A DERIVATIVE THEREOF AND AN ANTIMICROBIAL AGENT OR AN ANTIBIOTIC AGENT, AND THEIR USE FOR TREATING ORAL PATHOGENS AND OTHER DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2004-11-04 | — | — | WO | claimed |
| CN-1494902-A | Application of high-solubility berberine in preparation of medicine. | 吴开敏 | 2004-05-12 | — | — | CN | claimed |
| CN-1485326-A | Process for preparing berberine sulphate | 东北制药总厂 | 2004-03-31 | — | — | CN | claimed |
| CN-1481796-A | Medication for adiposity | 吴开敏 | 2004-03-17 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-4744952-A | Test paper for determining the concentration of halogen ions by filter paper chromatography, and manufacturing process for and use of the same | OGITA ZEN ICHI (JP) | 1988-05-17 | — | — | US | claimed |
| EP-0144409-A4 | LOCALIZATION OF CANCEROUS TISSUE BY MONITORING INFRARED FLUORESCENCE EMITTED BY INTRAVENOUSLY INJECTED PORPHYRIN IN TUMOR-SPECIFIC MARKERS EXCITED BY LONG WAVELENGTH LIGHT. | UNIV JOHNS HOPKINS (US) | 1987-10-05 | — | — | EP | claimed |
| US-4541438-A | Localization of cancerous tissue by monitoring infrared fluorescence emitted by intravenously injected porphyrin tumor-specific markers excited by long wavelength light | THE JOHNS HOPKINS UNIVERSITY (US) | 1985-09-17 | — | — | US | claimed |
| EP-0144409-A1 | LOCALIZATION OF CANCEROUS TISSUE BY MONITORING INFRARED FLUORESCENCE EMITTED BY INTRAVENOUSLY INJECTED PORPHYRIN IN TUMOR-SPECIFIC MARKERS EXCITED BY LONG WAVELENGTH LIGHT. | UNIV JOHNS HOPKINS (US) | 1985-06-19 | — | — | EP | claimed |
| WO-1984004665-A1 | LOCALIZATION OF CANCEROUS TISSUE BY MONITORING INFRARED FLUORESCENCE EMITTED BY INTRAVENOUSLY INJECTED PORPHYRIN IN TUMOR-SPECIFIC MARKERS EXCITED BY LONG WAVELENGTH LIGHT | UNIV JOHNS HOPKINS (US) | 1984-12-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171748-B2 | Nitroimidazole formulations | PHB1, COX5B, CYP3A5 | BCHE 287/4885ACHE 1722/4885EP300 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.